

26 *Authors' contribution statement:* All authors had access to the data and contributed significantly to
27 writing the manuscript.

28 **Manuscript details:**

29 Abstract word count: 327

30 Text word count: 3,515 (excluding abstract, declarations, acknowledgments, and references)

31 Number of references: 58

32 Number of tables: 2

33 Number of figures: 1

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53 **Abstract**

54 *Background:* The availability of an effective vaccine does not equate to its use; its effectiveness
55 primarily depends on vaccine acceptance by the targeted population. Despite the rapid development
56 and widespread access to the COVID-19 vaccine, herd immunity is yet to be achieved, with vaccine
57 hesitancy as a major barrier. This study sought to systematically assess the beliefs, attitudes, and
58 acceptance towards COVID-19 vaccines, including factors contributing to vaccination hesitancy in
59 the Eastern and Western hemispheres.

60 *Methods:* A comprehensive search of articles was conducted through Scopus, PubMed, Embase,
61 CINAHL, Cochrane CENTRAL, and Web of Science databases for studies published from inception
62 to May 2023 using the PRISMA guidelines.

63 *Results:* Our search yielded 1154, of which 21 were eligible for inclusion. The rate of willingness or
64 intention to vaccinate varied with the geographic region, from 12% in the USA to 93.9% in China.
65 Four studies from the Western and two from Eastern regions reported a low acceptance rate (defined
66 as <50%): USA (12%), Spain (48.3%), Switzerland (38.6%), Europe (multi-national, 31%), Nepal
67 (38.3%), and Oman (43%). Overall, vaccine acceptance was low-to-moderate in the general
68 population and healthcare workers (HCWs) in both Eastern and Western hemispheres except for
69 China which reported high acceptance (defined as >75%) among the general population and HCWs.
70 Demographic characteristics (female, younger age, and higher education) and non-demographic
71 factors (knowledge about the COVID-19 vaccine and its development, history of influenza
72 vaccination, perceived susceptibility or severity of infection, and the belief that vaccines are effective
73 in controlling the pandemic were associate with high acceptance rates or intentions to take the
74 COVID-19 vaccine. On the other hand, mistrust of the vaccine, its safety and effectiveness,
75 disinformation or poor awareness of the vaccine, side effects concerns, belief in natural immunity,
76 previous adverse experience with the vaccines, and distrust in the information sources about the
77 COVID-19 pandemic were associated with vaccination hesitancy.

78 *Conclusion:* For better acceptance, COVID-19 vaccination campaign strategies should be modeled
79 based on regional political, economic, and social contexts.

80 **Keywords:** COVID-19, vaccine, acceptance, systematic review, willingness, attitude, beliefs,
81 hesitancy, coronavirus.

82 **Highlights**

- 83 • The willingness to accept COVID-19 vaccines was low-to-moderate in both hemispheres.
84 • Healthcare workers were as willing to vaccinate as the general population.
85 • Vaccine hesitancy was associated with demographic and vaccine-specific factors.

86 **Introduction**

87 The COVID-19 pandemic is one of the most significant pandemics of the 21st century accounting for
88 over 767 million infections and nearly 7 million deaths as of July 2023 [1]. Due to its severity,
89 pandemic control measures such as social distancing were prioritized alongside developing novel
90 vaccines and pharmaceutical and biologic agents to treat patients with severe symptoms [2]. There is a
91 global consensus that vaccination is the imminent and ultimate key to controlling the COVID-19
92 pandemic. For instance, in May 2020, the 73rd World Health Assembly issued a resolution that
93 attributed comprehensive immunization as a global fundamental public health strategy to prevent,
94 contain and stop the spread of COVID-19 [3].

95 In response to the call, multiple COVID-19 vaccines were developed and tested across diverse
96 populations, signifying a significant breakthrough in vaccine development to contain the pandemic.
97 The US Food and Drug Administration issued the first emergency use authorization for the
98 BTN162b2 vaccine (Pfizer-BioNTech) on 11 December 2020 to inoculate young adults aged 16 years
99 and above [4]. Soon after, emergency use authorization was granted for mRNA-1273 (Moderna),
100 AZD1222 (Oxford/AstraZeneca), and Ad26.COV2.5 (Janssen) vaccines [5]. By the first quarter of
101 2021, there were 85 vaccine candidates in the clinical trial phase and 184 in the pre-clinical phase [6].

102 However, reluctance to accept a potential vaccine was reported even before the widespread
103 availability of COVID-19 vaccines in the general population and healthcare workers (HCWs) [7, 8].
104 COVID-19 vaccine hesitancy has been a barrier to scaling up the vaccination rate for achieving herd
105 immunity [9]. Vaccine hesitancy is a multi-factored phenomenon rooted in several factors such as an
106 individual's socio-political stand, religious convictions, trust in government or the healthcare system,
107 health/vaccine literacy, the source of information, and the perceived severity or risk of contracting the
108 disease [10]. These factors tend to aggregate with other vaccine-specific factors, and as a result, the
109 underlying cluster of factors of vaccine hesitancy varies by the vaccine. In the case of COVID-19, the
110 rapid development and regulatory approval of the vaccine, political affiliations, and widespread
111 misinformation about vaccine safety, efficacy, and disease severity have played a key role in low
112 public confidence in the vaccine [11, 12]. As a result, significant disparities in regional vaccination

113 rates have emerged. As of 26 June 2023, persons vaccinated with a complete primary series per 100
114 population stood at 31.5 for Africa, 51.3 for Eastern Mediterranean, 64.6 for Europe, 69.2 for South-
115 East Asia, 71.2 for the Americas, and 85.4 for Western Pacific regions [1].

116 Given the disparities in vaccination rates, region-specific interventions may be required to improve
117 the willingness to vaccinate. Although several studies have explored the factors associated with
118 COVID-19 at the country level, regional studies are scarce. Therefore, the present study sought to
119 conduct a systematic review of the current works of literature regarding the facets of vaccine
120 hesitancy, particularly the factors associated with the beliefs, attitudes, and acceptance of vaccines in
121 the Western and Eastern hemispheres.

122 **Methodology**

123 A rapid systematic review approach was utilized in conformity with the guidelines of the Preferred
124 Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) reporting statement [13] to
125 give valid and timely evidence that informs various decision-making concerning COVID-19
126 vaccination strategies.

127 *Search strategy*

128 A systematic literature search was conducted for relevant articles published from inception to May
129 2023 in the following databases with customized retrieval strategies for each database: Scopus
130 (Medline), PubMed, Embase, CINAHL, Cochrane CENTRAL, and Web of Science. Regarding the
131 search syntax, the controlled vocabulary involved generic free-text search terms such as 'population,'
132 'willingness,' 'attitude,' 'beliefs,' and 'vaccine hesitancy.' The MeSH vocabulary terms also included
133 'vaccine,' 'COVID-19 vaccines,' 'sars-cov-2 vaccine,' 'vaccination refusal,' '2019 novel coronavirus,'
134 and 'coronavirus.' The English synonyms were also used systematically as search syntax items in the
135 databases to minimize the chances of missing relevant studies. In addition, the lists of bibliographies
136 of the eligible articles and Google Scholar were manually searched to identify any potential reference
137 for inclusion.

138 *Inclusion and exclusion criteria*

139 The eligibility of the articles obtained from the database and bibliography searches was assessed using
140 the following inclusion criteria:

- 141 i. Studies involving the general public and/or HCWs. HCW was defined as persons employed
142 or studying within the healthcare facility, including physicians, medical students, and the
143 ancillary staff.
- 144 ii. Published primary studies inclusive of structured design, such as cross-sectional studies and
145 semi-structured surveys.
- 146 iii. Articles that examined the attitudes, acceptance, and or beliefs towards COVID-19
147 vaccination and any related factors. In this accord, vaccination acceptance was defined as the
148 percentage of the population willing to accept vaccination when available.
- 149 iv. The English language articles were prioritized for inclusion, and any other relevant articles
150 could be translated into English.

151 Duplicated studies, commentaries, case reports, protocols, editorials, letters, conference abstracts,
152 retracted, and articles in preprint were excluded. Articles not available online in full or from low-
153 quality sources were also excluded.

154 *Article screening and selection*

155 All the articles from the search were imported into the Endnote software [14] and deduplicated. Titles
156 and abstracts of the remaining articles were assessed, and those not meeting the inclusion criteria were
157 excluded. The remaining articles were subjected to full-text screening. If more than one article
158 utilized the same dataset, the one with the largest sample size was included.

159 Two reviewers (A.F. and J.L.) conducted article screening and selection. Any differences between the
160 reviewers were resolved through discussion. However, if the two reviewers could not arrive at a
161 consensus on excluding or including some articles, the senior reviewer (G.H.) was consulted.

162 *Data extraction and management*

163 Abstraction of all the relevant data was simultaneously performed by two reviewers (A.F. and J.L.)
164 independently using a standardized data extraction form and then exchanged for validation to prevent

165 data inconsistency and errors. Any disagreement was resolved through discussion with the third
166 reviewer (G.H.). Information that reflected the attitude or beliefs of the participants towards receiving
167 COVID-19 vaccines were sought through either of the following measurements: rate of COVID-19
168 vaccine acceptance or rejection, rate of positive/negative response to specific vaccine uptake, rate of
169 individuals willing to enroll in a COVID-19 vaccine trial. The other relevant significant information
170 that was sought included: the first author and publication year, the geographical context of the
171 participants (i.e., country/city/setting), study design, survey period, study population of interest and
172 sample sizes, data collection methods, demographic characteristics, and motivation and barriers
173 towards vaccine uptake (vaccine hesitancy factors).

174 The vaccine acceptance rate was defined as the proportion of the population who were willing to or
175 had taken the locally available COVID-19 vaccine and was categorized as low (<50%), moderate (50-
176 75%), and high (>75%).

177 *Evidence quality assessment and risk of bias*

178 The selected articles' methodological quality and risk of bias were assessed using the Newcastle-
179 Ottawa (NOS) quality scale independently by two reviewers (A.F. and J.L.). Any uncertainties were
180 resolved by consulting the third reviewer (G.H.). The NOS scale was developed to assess the quality
181 of non-randomized studies of their design, content, and ease of use. The NOS has seven quality
182 scoring systems under three main themes: selection, comparability, and outcome.

183 **Results**

184 *Search results and study selection*

185 Our database search returned 1,137 articles, with an additional 17 from manual reference list
186 screening. Seven hundred seventy-eight articles were removed during de-duplication. Titles and
187 abstracts of the remaining 367 studies were screened, of which 103 articles were eligible for full-text
188 screening. Finally, 21 articles fully meeting the inclusion criteria were identified and included in this
189 systematic review. The flow of study screening and selection is shown in **Figure 1**.

190 *Study characteristics*

191 The studies included in this review were published between 2020 and 2022, although most were
192 published in 2021 (n=16). All the included studies adopted a cross-sectional design and specifically
193 targeted adults aged above 18 years. The sample sizes ranged from 102 to 12,034 subjects.

194 Ten of the 21 studies were from the Eastern hemisphere encompassing India [15, 16], China [17, 18],
195 Indonesia [19], Nepal [20], Oman [21], Saudi Arabia [22, 23], and the United Arab Emirates [24].
196 Studies from the Western hemisphere originated from Spain [25], Switzerland [26], Poland [27],
197 Slovakia [28], USA [29-32], Canada [33], and Ecuador [34]. There was one European multi-national
198 study [35].

199 The detailed characteristics of the included studies are presented in **Table 1**.

200 *Quality appraisal & assessment*

201 The results of the quality appraisal for the included studies are presented in **Table 2**. Fifteen studies
202 scored six, while the rest scored five on the NOS quality scale, indicating good quality.

203 **Evidence Synthesis and Discussion**

204 *Summary of Key Findings*

205 A total of 21 studies were identified from 14 countries in the Eastern and Western hemispheres that
206 explored factors associated with attitudes, beliefs, and intentions to accept the COVID-19 vaccine.
207 Findings indicated that COVID-19 vaccine acceptance was low-to-moderate in both the general
208 population and HCWs. Demographic characteristics, including age, gender, education, and social
209 status, were strongly associated with the willingness to vaccinate against COVID-19. Additionally,
210 non-demographic factors such as sound knowledge about the COVID-19 vaccine and its development,
211 history of previous influenza vaccination, perceived risks (including fear of contracting the family,
212 protecting self, family, or community), the trustworthiness of the information source regarding
213 COVID-19 disease, and the beliefs that the virus can be prevented using the vaccine or a positive
214 attitude towards the vaccine and its efficacy were associate with high acceptance rates or intentions to
215 take the COVID-19 vaccine. On the other hand, mistrust of the vaccine, its safety and effectiveness,
216 disinformation or poor awareness of the vaccine, side effects concerns, belief in natural immunity,

217 previous adverse experience with the vaccines, and distrust in the information sources about the
218 COVID-19 pandemic were associated with vaccination hesitancy.

219 *Acceptance rates*

220 All but one article [15] evaluated the willingness to receive the COVID-19 vaccine. The rate of
221 willingness or intention to vaccinate varied with the geographic region from 12% in New York, USA
222 [31] to 93.9% in China [18]. Four studies from the Western and two from Eastern regions reported a
223 low acceptance rate: USA (12%) [31], Spain (48.3%) [25], Switzerland (38.6%) [26], Europe (multi-
224 national, 31%) [35], Nepal (38.3%) [20], and Oman (43%) [21].

225 *Demographic factors associated with attitude/beliefs/intention to accept the COVID-19 vaccine*

226 The factors associated with the beliefs, attitudes, and intentions toward COVID-19 vaccine
227 acceptance were analyzed in 11 of the included studies [20, 21, 24-26, 28, 29, 32-35], which used
228 either or both multivariate and univariate logistical regression analysis to account for the confounding
229 variables. The studies noted several demographic factors associated with COVID-19 vaccine uptake,
230 including age, gender, education level, occupation or social status, and race. Five studies reported that
231 the male sex strongly predicted acceptance or higher intentions to vaccinate against COVID-19 than
232 the female gender [20, 21, 24, 25, 33]. Of the seven studies that analyzed age, five studies [20, 21, 33-
233 35] indicated that being above 40 years strongly correlated with vaccine acceptance, while the other
234 two studies showed that younger age [24, 32] predicted the intention to take COVID-19 vaccine
235 among HCW and the general population. Six studies indicated that higher education levels [20, 25,
236 29, 33-35], especially degree attainment, strongly predicted higher intention towards COVID-19
237 vaccine acceptance, contrary to two studies that showed that low education attainment [24, 32] was
238 associated with a high likelihood of vaccination acceptance. Regarding social status, studies indicated
239 factors such as marriage, retirement, and high income as determinants of COVID-19 vaccine
240 acceptance [25]. Nevertheless, two studies reported that identifying as White was associated with a
241 greater intention to vaccinate than those identifying as Black, Asian, Hispanic, or others [30, 32].
242 Among HCWs, designation or the type of work was a strong predictor of vaccination [20, 28].

243 *Non-demographic factors associated with attitude/beliefs/intention to accept the COVID-19 vaccine*

244 The included studies also reported factors unrelated to population demographics that correlated with
245 the uptake of the COVID-19 vaccine. In particular, the high-risk perceptions towards COVID-19,
246 including fear of contracting the disease and perception towards protecting self, relatives, family, and
247 community was identified by eight studies as a significant contributor to acceptance and intention to
248 take COVID-19 vaccine [16, 20, 24, 27, 29, 30, 33, 34].

249 Furthermore, five studies weighed the belief that COVID-19 disease is preventable through
250 vaccination, a low risk of adverse effects, or a positive attitude towards the vaccine [15, 19, 21, 30,
251 34] as crucial contributors to vaccination acceptance. Four other studies identified sound knowledge
252 of the COVID-19 pandemic and vaccine development as important factors for accepting COVID-19
253 vaccination [18, 21, 23, 25]. Five studies also found that previous influenza vaccination correlated to
254 the likelihood of vaccination against coronavirus [22, 26-28, 32]. Trustworthiness of the health
255 information source about COVID-19, including media, authorities, and the government, also
256 emanated as a strong predictor in four included studies. The other crucial factors associated with
257 beliefs, attitudes, or intentions to take the COVID-19 vaccine included health statuses such as chronic
258 disease conditions, beliefs in conspiracy theories, willingness to recommend, coronavirus exposure or
259 previous diagnosis with COVID-19, and mandatory COVID-19 vaccination orders.

260 *Reasons for COVID-19 vaccine hesitancy (non-acceptance)*

261 Fifteen articles identified factors associated with COVID-19 vaccine hesitancy. Eight studies
262 identified the fear of developing severe side effects after vaccination [16, 17, 20, 24, 27, 28, 30, 32].
263 Most of the individuals who were skeptical of developing side effects considered the COVID-19
264 vaccines unsafe and thus rejected them. Individuals also failed to accept the vaccines due to mistrust;
265 rather, vaccination hesitancy was prompted since the targeted population showed distrust in the
266 efficacy or effectiveness of the vaccines to treat or minimize the Coronavirus (2019) pandemic.

267 Four studies highlighted disinformation, lack of or poor awareness of the COVID-19 vaccine, and its
268 efficacy as barriers to vaccine acceptance [18, 23, 25, 30]. Another critical variable was distrust in
269 COVID-19 information sources, which included pandemic-related loss of trust in physicians, the
270 health system, and the authorities [15, 24, 32]. Three studies also associated the belief in natural

271 immunity, or a belief in the perception that natural infection is better than vaccination for developing
272 immunity, as well as the anti-vaccine beliefs and attitudes to strongly predict vaccine hesitancy [15,
273 31, 32]. Other factors associated with vaccine hesitancy included the vaccine being new, previous
274 adverse effects or development of long-term side effects following COVID-19 vaccination, non-
275 exposure to COVID-19, lacking a recent vaccination history, and doubts about the severity of the
276 COVID-19 pandemic. One study identified demographic factors, such as female, retired, or
277 unemployed, as factors associated with non-acceptance of the COVID-19 vaccine [18].

278 *Regional variations in vaccine acceptance*

279 In the Eastern regions, vaccine acceptance varied from low in Nepal and Oman to moderate in India,
280 Indonesia, Saudi Arabia, and the United Arab Emirates. However, two studies from China reported
281 high vaccine acceptance rates. Consistent with our findings, a previous systematic review by Sallam
282 (2021) [36] found that vaccine acceptance in South-East Asia was relatively high (90%) compared to
283 Middle East countries (below 30%). Al-Jayyousi *et al.* (2021) [37] attributed the low acceptance of
284 the COVID-19 vaccine to the widespread beliefs in conspiracy theories that negatively impacted
285 vaccine uptake. Sallam (2021) [36] also cited low trust in the government and low education levels in
286 Middle East countries, resulting in a low willingness to vaccinate. COVID-19 vaccine hesitancy has
287 been reported in 6.3 to 56.2% of the population in South Asian countries, with safety and efficacy
288 concerns as predominant factors [38].

289 However, it is noteworthy that the two studies from China exclusively involved HCWs [18] and
290 cancer patients [17]. Contrary to our expectations, HCWs did not demonstrate a consistently higher
291 acceptance rate than the general population across the region. For instance, Paudel *et al.* (2021) [20]
292 sampled 266 Nepalese HCWs with an acceptance rate of 38.3%, Awaidy *et al.* (2022) [21] sampled
293 608 Omani HCWs with an acceptance rate of 43%, Jose *et al.* (2022) [16] sampled 403 India HCWs
294 with an acceptance rate of 54.6%, while Li *et al.* (2021) [18] reported a vaccine acceptance rate of
295 93.9% in a nationally representative sample of Chinese HCWs. These variations may be attributed to
296 the national mandate to vaccinate HCWs in some countries [39]. For instance, vaccination against

297 COVID-19 has been compulsory for all people employed at hospitals in China since the first quarter
298 of 2021 [40], while countries like India prioritized but did not mandate the vaccination of HCWs [41].
299 In the Western regions, low vaccination acceptance was reported from European countries [25-27]. In
300 contrast, one study from Canada [33] and two from the United States [29, 32] reported a moderate
301 vaccine acceptance rate among the general population. While another study from the United States
302 reported a very low acceptance rate of 12% [31], the participants were derived from a single
303 community (Haredi Orthodox Jewish Community). Our search strategy yielded only one article from
304 South America (Ecuador), which reported a high vaccine acceptance rate in the general population.
305 Although low high vaccine acceptance rates were reported among HCWs in Europe in the first quarter
306 of 2020, later surveys reported high vaccine acceptance rates [27, 28]. Vaccine acceptance among
307 HCWs in the United States remained moderate in late 2020 [30], on par with the general population.
308 Consistent with our findings, a recent meta-analysis reported 61% vaccine acceptance among general
309 populations and 55% among HCWs in the United States [42]. However, in the United States, low
310 vaccine acceptance may not be solely related to vaccine hesitancy. Instead, they may be driven by the
311 syngenetic effects of several factors such as gender (women), race (Black and Hispanic), age (younger
312 adults), political affiliations (Republican), low education and income, and residing in rural areas [42,
313 43]. Similarly, moderate vaccine acceptance rates have been reported in European countries in both
314 the general population and HCWs, with low trust/confidence in the vaccines, government and medical
315 system, and health/vaccine literacy as the main drivers of vaccine hesitancy [44, 45]. Even in the early
316 phase of vaccine rollout, Asian countries like China and South Korea reported higher vaccine
317 acceptance and greater trust in government than the United States, the United Kingdom, and European
318 countries [46, 47].
319 Concerns regarding the efficacy, safety, and effectiveness of the COVID-19 vaccines have been major
320 factors for vaccine hesitancy, while perceived susceptibility and severity of COVID-19, trust in the
321 government, and demographic factors such as female gender, younger age, higher educational
322 attainment, and high income have been associated with willingness to vaccinate throughout the
323 pandemic [46-54]. These vaccine refusal and acceptance predictors may be directly related to

324 COVID-19-related disinformation. As Al-Amer et al. (2022) [39] noted, myths, rumors, and false
325 beliefs on vaccines peddled by anti-vaccine individuals and media, especially social media, threatened
326 vaccination uptake. Similarly, Jin *et al.* (2021) [55] supported that the beliefs in conspiracy theories
327 circulated in the media by vaccine-averse individuals regarding the vaccine's side effects significantly
328 influenced people's decision to vaccinate. For instance, Reno *et al.* (2021) [56] showed that males
329 were less likely to believe in conspiracy theories and perceived greater severity of COVID-19 disease
330 and had a higher willingness to vaccinate, while Troiano *et al.* (2021) [57] demonstrated greater
331 concern towards the safety of the vaccines and distrusted the quality and impartiality of the vaccine
332 information among females with a negative effect on vaccine acceptance. Moreover, vaccine
333 hesitancy could also result from underestimating the risk and severity of infection. The history of
334 influenza vaccination was another critical facilitator of vaccine acceptance attitude, consistent with
335 other studies [7, 58].

336 *Strengths and Limitations*

337 This systematic review provides updated evidence on the beliefs, attitudes, and acceptance of
338 COVID-19 in both healthcare and non-healthcare workers in the Eastern and Western regions of the
339 world, which can assist in developing region-specific policies to mitigate potential outbreaks of severe
340 COVID-19 variants or other infectious diseases. Nonetheless, this study has several limitations that
341 limit the generalizability of comprehensiveness of the findings. First, we only included peer-reviewed
342 published articles with the potential risk of missing more recent data that may have been available in
343 the grey literature and preprints. Second, all included studies conducted online or through network
344 surveys, which could compromise participant selection, especially with low participant turnout or
345 response rate. Moreover, participation was voluntary in most studies, increasing the risk of selection
346 bias. Third, all included articles were cross-sectional studies, which are typically descriptive, thereby
347 limiting the scope of drawing comprehensive causal inferences. Besides, cross-sectional studies are
348 limited to a particular point in time. Inevitably, people's attitudes, willingness, and beliefs might have
349 changed over time to influence the acceptance of vaccines.

350 **Conclusion**

351 Most countries in Eastern and Western regions exhibited low-to-moderate vaccine acceptance rates in
352 the general population and HCWs. Demographic characteristics such as male gender, older age,
353 higher education attainment, and having high socio-economic status strongly related to the positive
354 attitude towards intentions to vaccinate. Other positive predictive factors included self-perceived
355 risks, including fear of contracting the virus, previous history of influenza vaccination, sound
356 knowledge of the vaccine, positive attitude towards the vaccine and its efficacy, trustworthiness of
357 information sources, and mandatory vaccination orders. On the other hand, safety, efficacy, and
358 effectiveness concerns, distrust of the authority or government and information sources, belief in
359 natural immunity, and disinformation were barriers that led to vaccine hesitancy. Therefore, COVID-
360 19 vaccination campaign strategies should be modeled based on regional political, economic, and
361 social contexts for better acceptance.

362 **References**

- 363 [1] WHO. Coronavirus (COVID-19) Dashboard. N.D. <https://covid19.who.int/> (Accessed: 06 July
364 2023)
- 365 [2] Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and Development on
366 Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS
367 Cent Sci. 2020;6:315-31. <https://doi.org/10.1021/acscentsci.0c00272>
- 368 [3] WHO. Resolutions and decisions. 73rd World Health Assembly. Geneva 2020.
369 https://apps.who.int/gb/ebwha/pdf_files/WHA73-REC1/A73_REC1-en.pdf#page=25 (Accessed: 06
370 July 2023)
- 371 [4] Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The Advisory
372 Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech
373 COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep.
374 2020;69:1922-4. <https://doi.org/10.15585/mmwr.mm6950e2>
- 375 [5] Kalinke U, Barouch DH, Rizzi R, Lagkadinou E, Tureci O, Pather S, et al. Clinical development
376 and approval of COVID-19 vaccines. Expert Rev Vaccines. 2022;21:609-19.
377 <https://doi.org/10.1080/14760584.2022.2042257>
- 378 [6] Ahmed S, Khan S, Imran I, Al Mughairbi F, Sheikh FS, Hussain J, et al. Vaccine Development
379 against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use. Vaccines
380 (Basel). 2021;9. <https://doi.org/10.3390/vaccines9080836>
- 381 [7] Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrahi M, Zigran A, et al. Vaccine hesitancy:
382 the next challenge in the fight against COVID-19. Eur J Epidemiol. 2020;35:775-9.
383 <https://doi.org/10.1007/s10654-020-00671-y>
- 384 [8] Roberts HA, Clark DA, Kalina C, Sherman C, Brislin S, Heitzeg MM, et al. To vax or not to vax:
385 Predictors of anti-vax attitudes and COVID-19 vaccine hesitancy prior to widespread vaccine
386 availability. PLoS One. 2022;17:e0264019. <https://doi.org/10.1371/journal.pone.0264019>

- 387 [9] Gerretsen P, Kim J, Quilty L, Wells S, Brown EE, Agic B, et al. Vaccine Hesitancy Is a Barrier to
388 Achieving Equitable Herd Immunity Among Racial Minorities. *Front Med (Lausanne)*.
389 2021;8:668299. <https://doi.org/10.3389/fmed.2021.668299>
- 390 [10] Dube E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J. Vaccine hesitancy: an overview.
391 *Hum Vaccin Immunother*. 2013;9:1763-73. <https://doi.org/10.4161/hv.24657>
- 392 [11] Hudson A, Montelpare WJ. Predictors of Vaccine Hesitancy: Implications for COVID-19 Public
393 Health Messaging. *Int J Environ Res Public Health*. 2021;18. <https://doi.org/10.3390/ijerph18158054>
- 394 [12] Sabahelzain MM, Hartigan-Go K, Larson HJ. The politics of Covid-19 vaccine confidence. *Curr*
395 *Opin Immunol*. 2021;71:92-6. <https://doi.org/10.1016/j.coi.2021.06.007>
- 396 [13] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA
397 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.
398 <https://doi.org/10.1136/bmj.n71>
- 399 [14] The EndNote Team. EndNote. EndNote 20 ed. Philadelphia, PA: Clarivate; 2013.
- 400 [15] Danabal KGM, Magesh SS, Saravanan S, Gopichandran V. Attitude towards COVID 19 vaccines
401 and vaccine hesitancy in urban and rural communities in Tamil Nadu, India - a community based
402 survey. *BMC Health Serv Res*. 2021;21:994. <https://doi.org/10.1186/s12913-021-07037-4>
- 403 [16] Jose S, Cyriac MC, Dhandapani M, Joseph J. COVID-19 vaccination intention and hesitancy:
404 Mistrust on COVID-19 vaccine benefit a major driver for vaccine hesitancy among healthcare
405 workers; a cross-sectional study in North India. *J Prev Med Hyg*. 2022;63:E219-E30.
406 <https://doi.org/10.15167/2421-4248/jpmh2022.63.2.1952>
- 407 [17] Hong J, Xu XW, Yang J, Zheng J, Dai SM, Zhou J, et al. Knowledge about, attitude and
408 acceptance towards, and predictors of intention to receive the COVID-19 vaccine among cancer
409 patients in Eastern China: A cross-sectional survey. *J Integr Med*. 2022;20:34-44.
410 <https://doi.org/10.1016/j.joim.2021.10.004>

- 411 [18] Li XH, Chen L, Pan QN, Liu J, Zhang X, Yi JJ, et al. Vaccination status, acceptance, and
412 knowledge toward a COVID-19 vaccine among healthcare workers: a cross-sectional survey in China.
413 *Hum Vaccin Immunother.* 2021;17:4065-73. <https://doi.org/10.1080/21645515.2021.1957415>
- 414 [19] Wirawan GBS, Mahardani P, Cahyani MRK, Laksmi N, Januraga PP. Conspiracy beliefs and
415 trust as determinants of COVID-19 vaccine acceptance in Bali, Indonesia: Cross-sectional study. *Pers*
416 *Individ Dif.* 2021;180:110995. <https://doi.org/10.1016/j.paid.2021.110995>
- 417 [20] Paudel S, Palaian S, Shankar PR, Subedi N. Risk Perception and Hesitancy Toward COVID-19
418 Vaccination Among Healthcare Workers and Staff at a Medical College in Nepal. *Risk Manag*
419 *Healthc Policy.* 2021;14:2253-61. <https://doi.org/10.2147/RMHP.S310289>
- 420 [21] Awaidy STA, Al Siyabi H, Khatiwada M, Al Siyabi A, Al Mukhaini S, Dochez C, et al.
421 Assessing COVID-19 Vaccine's Acceptability Amongst Health Care Workers in Oman: A cross-
422 sectional study. *J Infect Public Health.* 2022;15:906-14. <https://doi.org/10.1016/j.jiph.2022.06.005>
- 423 [22] Alshahrani SM, Dehom S, Almutairi D, Alnasser BS, Alsaif B, Alabdrabalnabi AA, et al.
424 Acceptability of COVID-19 vaccination in Saudi Arabia: A cross-sectional study using a web-based
425 survey. *Hum Vaccin Immunother.* 2021;17:3338-47. <https://doi.org/10.1080/21645515.2021.1936869>
- 426 [23] Samannodi M, Alwafi H, Naser AY, Alabbasi R, Alshahaf N, Alosaimy R, et al. Assessment of
427 caregiver willingness to vaccinate their children against COVID-19 in Saudi Arabia: a cross-sectional
428 study. *Hum Vaccin Immunother.* 2021;17:4857-64. <https://doi.org/10.1080/21645515.2021.2004054>
- 429 [24] Albahri AH, Alnaqbi SA, Alshaali AO, Alnaqbi SA, Shahdoor SM. COVID-19 Vaccine
430 Acceptance in a Sample From the United Arab Emirates General Adult Population: A Cross-Sectional
431 Survey, 2020. *Front Public Health.* 2021;9:614499. <https://doi.org/10.3389/fpubh.2021.614499>
- 432 [25] Rodriguez-Blanco N, Montero-Navarro S, Botella-Rico JM, Felipe-Gomez AJ, Sanchez-Mas J,
433 Tuells J. Willingness to Be Vaccinated against COVID-19 in Spain before the Start of Vaccination: A
434 Cross-Sectional Study. *Int J Environ Res Public Health.* 2021;18.
435 <https://doi.org/10.3390/ijerph18105272>

- 436 [26] Stuckelberger S, Favre G, Ceulemans M, Nordeng H, Gerbier E, Lambelet V, et al. SARS-CoV-2
437 Vaccine Willingness among Pregnant and Breastfeeding Women during the First Pandemic Wave: A
438 Cross-Sectional Study in Switzerland. *Viruses*. 2021;13. <https://doi.org/10.3390/v13071199>
- 439 [27] Szmyd B, Karuga FF, Bartoszek A, Staniecka K, Siwecka N, Bartoszek A, et al. Attitude and
440 Behaviors towards SARS-CoV-2 Vaccination among Healthcare Workers: A Cross-Sectional Study
441 from Poland. *Vaccines (Basel)*. 2021;9. <https://doi.org/10.3390/vaccines9030218>
- 442 [28] Ulbrichtova R, Svihrova V, Tatarkova M, Hudeckova H, Svihra J. Acceptance of COVID-19
443 Vaccination among Healthcare and Non-Healthcare Workers of Hospitals and Outpatient Clinics in
444 the Northern Region of Slovakia. *Int J Environ Res Public Health*. 2021;18.
445 <https://doi.org/10.3390/ijerph182312695>
- 446 [29] Ehde DM, Roberts MK, Herring TE, Alschuler KN. Willingness to obtain COVID-19
447 vaccination in adults with multiple sclerosis in the United States. *Mult Scler Relat Disord*.
448 2021;49:102788. <https://doi.org/10.1016/j.msard.2021.102788>
- 449 [30] Kuter BJ, Browne S, Momplaisir FM, Feemster KA, Shen AK, Green-McKenzie J, et al.
450 Perspectives on the receipt of a COVID-19 vaccine: A survey of employees in two large hospitals in
451 Philadelphia. *Vaccine*. 2021;39:1693-700. <https://doi.org/10.1016/j.vaccine.2021.02.029>
- 452 [31] Carmody ER, Zander D, Klein EJ, Mulligan MJ, Caplan AL. Knowledge and Attitudes Toward
453 Covid-19 and Vaccines Among a New York Haredi-Orthodox Jewish Community. *J Community*
454 *Health*. 2021;46:1161-9. <https://doi.org/10.1007/s10900-021-00995-0>
- 455 [32] Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM. Attitudes Toward a
456 Potential SARS-CoV-2 Vaccine : A Survey of U.S. Adults. *Ann Intern Med*. 2020;173:964-73.
457 <https://doi.org/10.7326/M20-3569>
- 458 [33] Dube E, Dionne M, Pelletier C, Hamel D, Gadio S. COVID-19 vaccination attitudes and
459 intention among Quebecers during the first and second waves of the pandemic: findings from repeated

- 460 cross-sectional surveys. Hum Vaccin Immunother. 2021;17:3922-32.
461 <https://doi.org/10.1080/21645515.2021.1947096>
- 462 [34] Jaramillo-Monge J, Obimpeh M, Vega B, Acurio D, Boven A, Verhoeven V, et al. COVID-19
463 Vaccine Acceptance in Azuay Province, Ecuador: A Cross-Sectional Online Survey. Vaccines
464 (Basel). 2021;9. <https://doi.org/10.3390/vaccines9060678>
- 465 [35] Kregar Velikonja N, Globevnik Velikonja V, Verdenik I, Jurisic I, Stanisavljevic S,
466 Dobrowolska B, et al. Vaccination intention among healthcare workers during the first wave of the
467 coronavirus disease 2019 pandemic in relation to knowledge: a cross-sectional study in Croatia,
468 Slovenia, Serbia, and Poland. Croat Med J. 2022;63:79-88. <https://doi.org/10.3325/cmj.2022.63.79>
- 469 [36] Sallam M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine
470 Acceptance Rates. Vaccines (Basel). 2021;9. <https://doi.org/10.3390/vaccines9020160>
- 471 [37] Al-Jayyousi GF, Sherbash MAM, Ali LAM, El-Heneidy A, Alhussaini NWZ, Elhassan MEA, et
472 al. Factors Influencing Public Attitudes towards COVID-19 Vaccination: A Scoping Review
473 Informed by the Socio-Ecological Model. Vaccines (Basel). 2021;9.
474 <https://doi.org/10.3390/vaccines9060548>
- 475 [38] Ennab F, Qasba RK, Uday U, Priya P, Qamar K, Nawaz FA, et al. COVID-19 vaccine hesitancy:
476 A narrative review of four South Asian countries. Front Public Health. 2022;10:997884.
477 <https://doi.org/10.3389/fpubh.2022.997884>
- 478 [39] Maneze D, Salamonson Y, Grollman M, Montayre J, Ramjan L. Mandatory COVID-19
479 vaccination for healthcare workers: A discussion paper. Int J Nurs Stud. 2023;138:104389.
480 <https://doi.org/10.1016/j.ijnurstu.2022.104389>
- 481 [40] Cheng Y, Li T, Zheng Y, Xu B, Bi Y, Hu Y, et al. Self-Reported adverse events among Chinese
482 healthcare workers immunized with COVID-19 vaccines composed of inactivated SARS-CoV-2.
483 Hum Vaccin Immunother. 2022;18:2064134. <https://doi.org/10.1080/21645515.2022.2064134>

- 484 [41] Purohit N, Chugh Y, Bahuguna P, Prinja S. COVID-19 management: The vaccination drive in
485 India. *Health Policy Technol.* 2022;11:100636. <https://doi.org/10.1016/j.hlpt.2022.100636>
- 486 [42] Dhanani LY, Franz B. A meta-analysis of COVID-19 vaccine attitudes and demographic
487 characteristics in the United States. *Public Health.* 2022;207:31-8.
488 <https://doi.org/10.1016/j.puhe.2022.03.012>
- 489 [43] Hu S, Xiong C, Li Q, Wang Z, Jiang Y. COVID-19 vaccine hesitancy cannot fully explain
490 disparities in vaccination coverage across the contiguous United States. *Vaccine.* 2022;40:5471-82.
491 <https://doi.org/10.1016/j.vaccine.2022.07.051>
- 492 [44] Popa AD, Enache AI, Popa IV, Antoniu SA, Dragomir RA, Burlacu A. Determinants of the
493 Hesitancy toward COVID-19 Vaccination in Eastern European Countries and the Relationship with
494 Health and Vaccine Literacy: A Literature Review. *Vaccines (Basel).* 2022;10:672.
495 <https://doi.org/10.3390/vaccines10050672>
- 496 [45] Heyerdahl LW, Vray M, Lana B, Tvardik N, Gobat N, Wanat M, et al. Conditionality of
497 COVID-19 vaccine acceptance in European countries. *Vaccine.* 2022;40:1191-7.
498 <https://doi.org/10.1016/j.vaccine.2022.01.054>
- 499 [46] Lin C, Tu P, Beitsch LM. Confidence and Receptivity for COVID-19 Vaccines: A Rapid
500 Systematic Review. *Vaccines (Basel).* 2020;9. <https://doi.org/10.3390/vaccines9010016>
- 501 [47] Wang Q, Yang L, Jin H, Lin L. Vaccination against COVID-19: A systematic review and meta-
502 analysis of acceptability and its predictors. *Prev Med.* 2021;150:106694.
503 <https://doi.org/10.1016/j.ypmed.2021.106694>
- 504 [48] Kreps S, Prasad S, Brownstein JS, Hswen Y, Garibaldi BT, Zhang B, et al. Factors Associated
505 With US Adults' Likelihood of Accepting COVID-19 Vaccination. *JAMA Netw Open.*
506 2020;3:e2025594. <https://doi.org/10.1001/jamanetworkopen.2020.25594>

- 507 [49] Pogue K, Jensen JL, Stancil CK, Ferguson DG, Hughes SJ, Mello EJ, et al. Influences on
508 Attitudes Regarding Potential COVID-19 Vaccination in the United States. *Vaccines (Basel)*. 2020;8.
509 <https://doi.org/10.3390/vaccines8040582>
- 510 [50] Schwarzinger M, Watson V, Arwidson P, Alla F, Luchini S. COVID-19 vaccine hesitancy in a
511 representative working-age population in France: a survey experiment based on vaccine
512 characteristics. *Lancet Public Health*. 2021;6:e210-e21. [https://doi.org/10.1016/S2468-](https://doi.org/10.1016/S2468-2667(21)00012-8)
513 [2667\(21\)00012-8](https://doi.org/10.1016/S2468-2667(21)00012-8)
- 514 [51] Al-Amer R, Maneze D, Everett B, Montayre J, Villarosa AR, Dwekat E, et al. COVID-19
515 vaccination intention in the first year of the pandemic: A systematic review. *J Clin Nurs*. 2022;31:62-
516 86. <https://doi.org/10.1111/jocn.15951>
- 517 [52] Miyachi T, Takita M, Senoo Y, Yamamoto K. Lower trust in national government links to no
518 history of vaccination. *Lancet*. 2020;395:31-2. [https://doi.org/10.1016/S0140-6736\(19\)32686-8](https://doi.org/10.1016/S0140-6736(19)32686-8)
- 519 [53] Larson HJ, Clarke RM, Jarrett C, Eckersberger E, Levine Z, Schulz WS, et al. Measuring trust in
520 vaccination: A systematic review. *Hum Vaccin Immunother*. 2018;14:1599-609.
521 <https://doi.org/10.1080/21645515.2018.1459252>
- 522 [54] Lee C, Whetten K, Omer S, Pan W, Salmon D. Hurdles to herd immunity: Distrust of
523 government and vaccine refusal in the US, 2002-2003. *Vaccine*. 2016;34:3972-8.
524 <https://doi.org/10.1016/j.vaccine.2016.06.048>
- 525 [55] Jin Q, Raza SH, Yousaf M, Zaman U, Siang J. Can Communication Strategies Combat COVID-
526 19 Vaccine Hesitancy with Trade-Off between Public Service Messages and Public Skepticism?
527 Experimental Evidence from Pakistan. *Vaccines (Basel)*. 2021;9.
528 <https://doi.org/10.3390/vaccines9070757>
- 529 [56] Reno C, Maietti E, Fantini MP, Savoia E, Manzoli L, Montalti M, et al. Enhancing COVID-19
530 Vaccines Acceptance: Results from a Survey on Vaccine Hesitancy in Northern Italy. *Vaccines*
531 (Basel). 2021;9. <https://doi.org/10.3390/vaccines9040378>

532 [57] Troiano G, Nardi A. Vaccine hesitancy in the era of COVID-19. *Public Health*. 2021;194:245-51.

533 <https://doi.org/10.1016/j.puhe.2021.02.025>


534 [58] Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among adults in the

535 United States: How many people would get vaccinated? *Vaccine*. 2020;38:6500-7.

536 <https://doi.org/10.1016/j.vaccine.2020.08.043>

537

538 **Figures & Tables**



539

540 **Figure 1:**PRISMA flow chart for study screening and selection process.

541

Table 1: Summary of the included studies.

Region & Author	Survey Characteristics [§]			Vaccine acceptance rate	Predictors of COVID-19 vaccine uptake	Predictors of COVID-19 vaccine hesitancy
	Period	Modality	Population			
Tamil Nadu, India Danabal <i>et al.</i> (2021) [15]	Jan 2021	Physical	564 GP participants ≥18 years	Not reported	<ul style="list-style-type: none"> Trust in the effectiveness of the vaccines. 	<ul style="list-style-type: none"> Mistrust in the health system or vaccines. Preference for natural immunity compared to vaccines.
Chandigarh, India Jose <i>et al.</i> (2022) [16]	Jan 2021	Online	403 HCW participants ≥18 years	54.6%	<ul style="list-style-type: none"> Perceived susceptibility or severity of infections. Not concerned about the efficacy of new vaccines. 	<ul style="list-style-type: none"> Concerns about vaccine safety in terms of quality control & side effects. Doubt on efficacy.
Eastern China Hong <i>et al.</i> (2022) [17]	Jun-Sept 2021	Online	2,158 cancer patients ≥18 years	75.95%	<ul style="list-style-type: none"> Alcohol consumption vs. non-drinkers. Income impacted by the pandemic. Knowledge vaccine development. Believing in the safety of the vaccine. Willingness to pay or recommend families & friends to get vaccinated. 	<ul style="list-style-type: none"> Being retired or unemployed. Undergoing multiple cancer therapies. Concerns that the vaccine might deteriorate the prognosis of cancer
China (National sample) Li <i>et al.</i> (2021) [18]	Jan-Feb 2021	Online	1,779 HCW participants ≥18 years	93.9%	<ul style="list-style-type: none"> High or medium knowledge level about COVID-19 vaccines. 	<ul style="list-style-type: none"> Demographics: Being female or a nurse, college degree. Low level of COVID-19 vaccine knowledge. Non-exposure to COVID-19.
Bali, Indonesia Wirawan <i>et al.</i> (2021) [19]	Sep-Oct 2020	Online	779 GP participants aged 24 (20–26) years	60.8%	<ul style="list-style-type: none"> Conspiracy beliefs, trust in conventional media & authoritative sources of information. 	<ul style="list-style-type: none"> Not reported

Pokhara, Nepal	Jan-Feb 2021	Physical & online	266 participants ≥18 years	HCW	38.3%	<ul style="list-style-type: none"> • Demographics: Being male, high income or education, designation (managerial & admin. staffs). • Prior SARS-CoV-2 diagnosis. • Perception about the severity of the pandemic. 	<ul style="list-style-type: none"> • Concern about vaccine safety.
Oman (National Sample) <i>Awaidy et al. (2022) [21]</i>	Dec 2020	Online	608 participants ≥20 years	HCW	43%	<ul style="list-style-type: none"> • Demographics: Being male. • Perceived adverse events (less) after vaccination. • Positive attitude towards the vaccine. • Trust in the government. • Having sound knowledge of the COVID-19 vaccine. 	<ul style="list-style-type: none"> • Previous experience with SARS-CoV-2.
Saudi Arabia (National Sample) <i>Alshahrani et al. (2021) [22]</i>	Jan 2021	Online	758 participants ≥18 years	GP	64%	<ul style="list-style-type: none"> • Trust in the source of health information about COVID-19. • Perception toward whether the vaccine is effective on emerging variants. • Previous uptake of the influenza vaccine. • Potential mandatory vaccination for international travel. 	<ul style="list-style-type: none"> • Not reported
Saudi Arabia (National Sample) <i>Samannodi et al. (2021) [23]</i>	Jun-Jul 2021	Online	581 participants ≥18 years	GP	63.9%	<ul style="list-style-type: none"> • Adequate information about the COVID-19 vaccine. 	<ul style="list-style-type: none"> • Poor awareness about the vaccine's effectiveness.
United Arab Emirates (National Sample) <i>Albahri et al. (2021) [24]</i>	Sep 2020	Online	2,705 participants ≥18 years	GP	60.1%	<ul style="list-style-type: none"> • Demographics: male gender, race (non-Emiratis), younger age group, & low educational attainment. • Perceived increased personal or public risk of contracting the disease. Increased perception of serious outcomes from the disease. 	<ul style="list-style-type: none"> • Unemployment. • No history of recent vaccination. • Doubting the severity of the situation or the vaccine's ability to control the pandemic.

						<ul style="list-style-type: none"> • Mistrust in information from public authorities & their abilities to handle the pandemic.
Spain (National Sample) Rodriguez-Blanco <i>et al.</i> (2021) [25]	Nov-Dec 2020	Online	2,501 GP participants aged 40.2±13.6 years	48.3%	<ul style="list-style-type: none"> • Demographics: Male gender, older than 60, married, retired, high-level education. • Health status: Hypertension, immunodepression, hypercholesterolemia, respiratory disease, or overweight. 	<ul style="list-style-type: none"> • Disinformation. • Lack of political consensus.
Switzerland (National Sample) Stuckelberger <i>et al.</i> (2021) [26]	Jun-Jul 2020	Online	1,551 pregnant or breastfeeding women ≥18 years	Pregnant = 29.7% Breastfeeding = 38.6%	<ul style="list-style-type: none"> • Demographics: Age older than 40 years & higher educational level. • History of influenza vaccination within the previous year. • Obstetricians as the primary healthcare practitioner. • Being in their third trimester of pregnancy. 	<ul style="list-style-type: none"> • Not reported
Łódź, Poland Szmyd <i>et al.</i> (2021) [27]	Dec 2020 - Jan 2021	Online	2,300 HCW participants Age: HCW = 31.4±8.4; Control = 26.9±9.05	HCW = 82.95 Control = 54.31%	<ul style="list-style-type: none"> • Positive medical history of recommended vaccinations. • Fear of catching SARS-CoV-2. • Fear of passing on the disease to relatives. 	<ul style="list-style-type: none"> • Development of long-term side effects after getting the vaccine. • Depression
Northern Slovakia Ulbrichtova <i>et al.</i> (2021) [28]	Aug-Sept 2021	Online	582 physicians, 542 non-physician HCW, 153 non-HCW aged 48.3±12.6 years	84.3%	<ul style="list-style-type: none"> • Physician job type. • History of SARS-CoV-2 or influenza vaccination. • Compulsory vaccination for HCWs, & compulsory vaccination for selected groups. 	<ul style="list-style-type: none"> • Mistrust in the efficacy of the vaccine. • Concerns of safety & side effects of the vaccines. • Contraindications or expect a complicated vaccination course.
Central/Eastern Europe Kregar	Apr-May 2020	Online	623 HCW participants (304, 86, 90, &	31%	<ul style="list-style-type: none"> • Demographics: Age (adults) & educational level (higher). • Knowledge about the pandemic 	<ul style="list-style-type: none"> • Not reported

Velikonja <i>et al.</i> (2022) [35]			143 from Croatia, Slovenia, Serbia, & Poland, respectively)					
United States (National Sample) Ehde <i>et al.</i> (2021) [29]	Apr-May 2020	Online	486 GP participants with multiple sclerosis ≥18 years	66.0%	<ul style="list-style-type: none"> • Demographics (higher education levels) • Higher perception of infection susceptibility. • Perceived trustworthiness of information sources 	<ul style="list-style-type: none"> • Not reported 		
Philadelphia, United States Kuter <i>et al.</i> (2021) [30]	Nov-Dec 2020	Online	12,034 HCW participants ≥18 years	63.7%	<ul style="list-style-type: none"> • Protecting themselves, their family, or the community. • Belief that vaccination is the best measure to prevent becoming seriously ill from SARS-CoV-2. • Personal health status/ vaccination history, Exposure to SARS-CoV-2 	<ul style="list-style-type: none"> • Concern about side effects/getting infected from the vaccine. • Vaccines being too new, less information/not knowing enough about the vaccine. • Mistrust/concerns about the vaccine not working. 		
New York, United States. Carmody <i>et al.</i> (2021) [31]	Dec 2020 - Jan 2021	Physical	102 participants from Haredi □ Orthodox Jewish Community aged 32 (25–38) years	12%	<ul style="list-style-type: none"> • Not reported 	<ul style="list-style-type: none"> • Belief that natural infection is better than vaccination for developing immunity. • Agreement that prior infection provides a path toward resuming communal life. • Pandemic-related loss of trust in physicians. 		

United States (National Sample) Fisher <i>et al.</i> (2020) [32]	Apr 2020	Physical & online	991 participants ≥ 18 years	GP	57.6%	<ul style="list-style-type: none"> • Demographics: Younger age, Black race, & lower educational attainment. • Not having received the influenza vaccine in the prior year. 	<ul style="list-style-type: none"> • Vaccine-specific concerns. • The need for more information. • Anti-vaccine attitudes or beliefs. • Lack of trust.
Quebec, Canada Dube <i>et al.</i> (2021) [33]	Mar-Dec 2020	Online	6,037 participants ≥ 18 years	GP	76%-66% in 1 st & 2 nd wave	<ul style="list-style-type: none"> • Demographics: Male gender, older age (60 years of age & over), university education. • Chronic medical status/ conditions (having or living with someone with chronic medical conditions). • Increased risk perceptions of COVID-19. 	<ul style="list-style-type: none"> • Not reported
Azuay province, Ecuador Jaramillo-Monge <i>et al.</i> (2021) [34]	Feb 2021	Online	1,219 participants aged 32 \pm 13 years	GP	91%	<ul style="list-style-type: none"> • Demographics: Older age, higher education levels (postgraduate education). • History of a negative COVID-19 test. • Higher perception of infection susceptibility. • Belief that COVID-19 infection can be prevented with a vaccine. 	<ul style="list-style-type: none"> • Not reported

[§] All studies were cross-sectional and conducted questionnaire-based surveys. Age data are presented as mean \pm SD or median (IQR) whenever available. GP = General population, HCW = Health care workers. [§].

Table 1: Newcastle-Ottawa scale scores for quality appraisal

Study	Selection			Comparability		Outcome	Total score
	Representativeness of the exposed cohort	Selection of non-exposed/ non-respondents	Ascertainments of exposure	Demonstration that outcome of interest was not present at the start of the study	Based on design	Based on analysis	
Danabal <i>et al.</i> (2021) [15]	1	0	1	1	1	1	6
Jose <i>et al.</i> (2022) [16]	1	0	1	1	1	0	5
Hong <i>et al.</i> (2022) [17]	1	0	1	1	1	1	6
Li <i>et al.</i> (2021) [18]	1	0	1	1	1	1	6
Wirawan <i>et al.</i> (2021) [19]	1	0	1	1	1	1	6
Paudel <i>et al.</i> (2021) [20]	1	0	1	1	1	1	6
Awaidy <i>et al.</i> (2022) [21]	1	0	1	1	1	1	6
Alshahrani <i>et al.</i> (2021) [22]	1	0	1	1	1	1	6
Samannodi <i>et al.</i> (2021) [23]	1	0	1	1	1	1	6
Albahri <i>et al.</i> (2021) [24]	1	0	1	1	1	0	5
Rodriguez-Blanco <i>et al.</i> (2021) [25]	1	0	1	1	1	1	6
Stuckelberger <i>et al.</i> (2021) [26]	1	0	1	1	1	1	6
Szmyd <i>et al.</i> (2021) [27]	1	0	1	1	1	0	5
Ulbrichtova <i>et</i>	1	0	1	1	1	1	6

al. (2021) [28]									
Ehde et al. (2021) [29]	1	0	1	1	1	0	1	5	
Kuter et al. (2021) [30]	1	0	1	1	1	1	1	6	
Carmody et al. (2021) [31]	1	0	1	1	1	0	1	5	
Fisher et al. (2020) [32]	1	0	1	1	1	0	1	5	
Dube et al. (2021) [33]	1	0	1	1	1	1	1	6	
Jaramillo-Monge et al. (2021) [34]	1	0	1	1	1	1	1	6	
Kregar Velikonja et al. (2022) [35]	1	0	1	1	1	1	1	6	